CNSP net incomeQ2 2026-$2.59M
CNSP net income was -$2.59M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.38M a year earlier. For the full fiscal 2025 it was -$15.85M, compared with -$14.86M in fiscal 2024.
CNS Pharmaceuticals Inc. (CNSP) financials
For the twelve months ended Jun 30, 2026, CNS Pharmaceuticals Inc. reported -$16.70M of net income.
- Net income, TTM
- -$16.70M
- Cash
- $19.98M
- Total debt
- $300.0K
- Market cap
- $5.3M
FY2022FY2023
FY2018FY2025
FY2018FY2025
CNSP revenue and earnings growth
CNSP EPSQ2 2026-$0.38
CNSP diluted EPS was -$0.38 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$35.75.
CNSP free cash flowQ2 2026-$3.54M
CNSP free cash flow was -$3.54M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.34M a year earlier. For the full fiscal 2025 it was -$13.83M, compared with -$17.12M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $27.7K | $0 | - | - | - | - |
| Research and development | $9.77M | $9.29M | $14.10M | $9.30M | $9.81M | $5.06M | $1.85M | $21.3K |
| Selling, general and admin | $6.21M | $5.61M | $4.77M | $5.97M | $4.68M | $4.39M | $1.98M | $860.5K |
| Operating income | -$15.99M | -$14.90M | -$18.87M | -$15.27M | -$14.49M | -$9.45M | -$3.83M | -$881.8K |
| Interest expense | $15.2K | $16.1K | $13.8K | $7.0K | $9.3K | $3.3K | $26.2K | $28.6K |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$15.85M | -$14.86M | -$18.85M | -$15.27M | -$14.50M | -$9.46M | -$3.88M | -$7.39M |
| EPS, basic | -$35.75 | -$466.89 | -$12509.11 | -$561.00 | -$825.00 | -$28.50 | -$14.00 | -$35.00 |
| EPS, diluted | -$35.75 | -$466.89 | -$12509.11 | -$561.00 | -$825.00 | -$28.50 | -$14.00 | -$35.00 |
| Diluted shares | 443,369 | 31,823 | 1,507 | 27,234.74 | 17,568.86 | 332,368.82 | 272,958.16 | 210,211.02 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.20M | $6.46M | $548.7K | $10.06M | $5.00M | $14.04M | $7.24M | $555.1K |
| Current assets | $8.10M | $8.66M | $1.59M | $12.56M | $7.48M | $15.50M | $7.89M | $588.1K |
| Total assets | $8.62M | $8.70M | $1.70M | $13.05M | $8.76M | $15.85M | $7.91M | $683.3K |
| Current liabilities | $4.10M | $2.52M | $6.13M | $4.92M | $2.59M | $1.91M | $311.0K | $1.23M |
| Short-term debt | - | - | - | - | - | $482.4K | - | - |
| Total debt | $300.0K | - | - | - | - | - | - | - |
| Total liabilities | $4.10M | $2.52M | $6.13M | $4.92M | $2.59M | $1.91M | $311.0K | $1.23M |
| Shareholders' equity | $4.52M | $6.18M | -$4.43M | $8.13M | $6.16M | $13.95M | $7.60M | -$549.3K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.81M | -$17.11M | -$14.14M | -$10.56M | -$13.54M | -$7.32M | -$3.55M | -$716.4K |
| Capital expenditures | $18.2K | $4.2K | $3.9K | $4.4K | $5.7K | $17.9K | $20.1K | $0 |
| Free cash flow | -$13.83M | -$17.12M | -$14.14M | -$10.56M | -$13.54M | -$7.34M | -$3.57M | -$716.4K |
| Investing cash flow | -$18.2K | -$4.2K | -$3.9K | -$4.4K | -$5.7K | -$17.9K | -$20.1K | $0 |
| Financing cash flow | $14.57M | $23.03M | $4.64M | $15.61M | $4.51M | $14.13M | $10.26M | $1.16M |
| Stock-based compensation | $187.7K | $839.0K | $1.01M | $1.20M | $1.72M | $1.29M | $477.1K | $110.2K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | - | - | -68137.1% | - | - | - | - | - |
| Net margin | - | - | -68086.9% | - | - | - | - | - |
| Free cash flow margin | - | - | -51085.1% | - | - | - | - | - |
| Return on equity | -350.4% | -240.5% | - | -187.8% | -235.2% | -67.8% | -51.0% | - |
| Return on assets | -183.8% | -170.8% | -1108.3% | -117.0% | -165.5% | -59.7% | -49.0% | -1081.7% |
| Current ratio | 1.98 | 3.43 | 0.26 | 2.55 | 2.88 | 8.13 | 25.38 | 0.48 |
| Debt to equity | 0.07 | - | - | - | - | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $6.7K | $7.0K | $12.9K |
| Research and development | $1.20M | $3.54M | $3.17M | $2.20M | $1.17M | $3.24M | $1.50M | $4.24M | $1.12M | $2.43M | $4.27M | $3.41M |
| Selling, general and admin | $1.50M | $1.43M | $2.82M | $1.06M | $1.24M | $1.09M | $1.70M | $1.38M | $1.41M | $1.11M | $1.11M | $1.12M |
| Operating income | -$2.70M | -$4.98M | -$5.99M | -$3.25M | -$2.41M | -$4.34M | -$3.20M | -$5.63M | -$2.53M | -$3.54M | -$5.38M | -$4.53M |
| Interest expense | $4.0K | $6.1K | $2.7K | $2.1K | $4.0K | $6.2K | $2.8K | $2.3K | $4.5K | $6.6K | $2.9K | $1.8K |
| Net income | -$2.59M | -$4.94M | -$5.96M | -$3.22M | -$2.38M | -$4.30M | -$3.18M | -$5.61M | -$2.53M | -$3.54M | -$5.38M | -$4.52M |
| EPS, basic | -$0.38 | -$7.30 | - | -$5.76 | -$6.42 | -$18.93 | - | -$153.20 | -$4049.20 | -$1020.48 | - | -$54.14 |
| EPS, diluted | -$0.38 | -$7.30 | - | -$5.76 | -$6.42 | -$18.93 | - | -$153.20 | -$4049.20 | -$1020.48 | - | -$54.14 |
| Diluted shares | 6.8M | 676,172 | - | 558,868 | 370,127 | 227,220 | - | 36,593 | 625 | 3,474 | - | 83,542 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $19.98M | $2.95M | $7.20M | $9.86M | $12.13M | $13.05M | $6.46M | $6.97M | $1.49M | $815.2K | $548.7K | $909.5K |
| Current assets | $21.92M | $4.08M | $8.10M | $11.39M | $14.14M | $13.72M | $8.66M | $7.39M | $2.15M | $1.60M | $1.59M | $2.06M |
| Total assets | $21.94M | $4.65M | $8.62M | $11.87M | $14.51M | $13.75M | $8.70M | $7.41M | $2.47M | $1.66M | $1.70M | $2.33M |
| Current liabilities | $3.74M | $4.58M | $4.10M | $1.96M | $1.38M | $2.78M | $2.52M | $4.06M | $6.76M | $6.09M | $6.13M | $4.07M |
| Total debt | $300.0K | - | $300.0K | - | - | - | - | - | - | - | - | - |
| Total liabilities | $3.74M | $4.58M | $4.10M | $1.96M | $1.38M | $2.78M | $2.52M | $4.06M | $6.76M | $6.09M | $6.13M | $4.07M |
| Shareholders' equity | $18.20M | $71.0K | $4.52M | $9.91M | $13.13M | $10.97M | $6.18M | $3.35M | -$4.29M | -$4.43M | -$4.43M | -$1.74M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.54M | -$4.65M | -$3.05M | -$2.17M | -$5.34M | -$3.24M | -$5.47M | -$6.80M | -$1.65M | -$3.19M | -$2.54M | -$3.38M |
| Capital expenditures | $3.8K | $6.2K | - | - | $0 | $0 | $4.2K | - | - | - | $2.2K | $1.7K |
| Free cash flow | -$3.54M | -$4.65M | - | - | -$5.34M | -$3.24M | -$5.48M | - | - | - | -$2.54M | -$3.38M |
| Investing cash flow | -$3.8K | -$6.2K | - | - | $0 | $0 | -$4.2K | - | - | - | -$2.2K | -$1.7K |
| Financing cash flow | $20.58M | $404.7K | $406.9K | -$92.0K | $4.43M | $9.83M | $4.96M | $12.28M | $2.33M | $3.46M | $2.18M | $8.4K |
| Stock-based compensation | $2.0K | $2.6K | $85.1K | $18.7K | $22.0K | $62.4K | $129.9K | $271.8K | $234.3K | $202.9K | $232.7K | $194.8K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | - | - | - | - | - | - | - | - | - | -52664.6% | -76826.2% | -35192.4% |
| Net margin | - | - | - | - | - | - | - | - | - | -52663.0% | -76767.4% | -35106.7% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - | -36254.1% | -26221.1% |
| Current ratio | 5.86 | 0.89 | 1.98 | 5.81 | 10.22 | 4.94 | 3.43 | 1.82 | 0.32 | 0.26 | 0.26 | 0.51 |
| Debt to equity | 0.02 | - | 0.07 | - | - | - | - | - | - | - | - | - |
Source: XBRL data CNS Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-50, first reported Aug 14, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CNSP peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CNSP | - | - | -$16.70M | - | $5.3M |
| KZIA | A$42.0K | -98.2% | -A$20.70M | -49290.5% | $115.5M |
| NVCR | $725.39M | +12.9% | -$121.73M | -16.8% | $1.40B |
| DNLI | $21.38M | - | -$314.42M | -1470.5% | $3.16B |
CNSP FAQ
4 questionsIs CNSP profitable?
No. CNS Pharmaceuticals Inc. reported a net loss of $16.70M for the twelve months ended Jun 30, 2026.How much cash and debt does CNSP have?
CNS Pharmaceuticals Inc. reported $19.98M in cash and cash equivalents and $300.0K of debt on its most recent balance sheet in SEC filings.When did CNSP last report financial results?
The latest statements here come from CNS Pharmaceuticals Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.Where does this CNSP financial data come from?
Quantisnow builds these statements from the structured XBRL data CNS Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.